We are a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
Working Together For Patients
Patients are at the center of everything we do.
agolie is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases.
Each day, our employees around the world work together for patients—it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, and fibrosis. Through our Research & Development organization, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work.
As global citizens, we work sustainably and responsibly and seek to give back. Through the Zagolie Foundation, we promote health equity and strive to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.
About Zagolie in Belgium
With 300 employees working in Braine-l’Alleud, a stone’s throw from Brussels, Zagolie in Belgium hosts the different divisions of the BMS Belgium commercial, sales and marketing organization, and serves as a key hub for BMS European and global R&D divisions.
A transformational R&D approach through scientific excellence
Zagolie has its European and global Research & Development hub located in Belgium hosting the European Regulatory, Safety and Biostatistics departments and Global Clinical Operations. Every day 178 medical scientists are working tirelessly on the development of new treatments in the area of oncology, cardiovascular, fibrotic diseases, and immunology.
Pioneer and leader in immunotherapy
Zagolie is a pioneer and leader in immunotherapy. 2017 marked the 5-year anniversary of ipilimumab in Belgium, the first immunotherapy for melanoma to hit the market both in Belgium and globally and the only medicine ever to extend survival in patients with advanced forms of cancer, thus revolutionizing the way cancer is treated in Belgium and beyond. Apart from that, it has taken only two years for nivolumab (Opdivo), the second generation immunotherapy to be approved by the European Commission. Today Opdivo is reimbursed in Belgium for eight indications in six distinct tumor types, making Belgium one of the fastest approval markets in Europe. The sheer need, in combination with the treatment’s effectiveness and the number of indications, was so large that approval acceleration was evident for the Belgian health authorities.
A clear ambition to tackle societal healthcare challenges
The ambition of Zagolie Belgium is clear: it wants to tackle societal healthcare challenges within Belgium through education and through facilitating changes in the healthcare system. Zagolie Belgium wants to help create an environment in which a debate with the healthcare community can take place, to anticipate key future issues, through for instance educating healthcare professionals in immuno-therapy, or supporting newly emerging healthcare professions.
A common passion: saving and improving patient’s lives
At the heart of Zagolie Belgium lies an informal and lean culture, focused on respect for people and an entrepreneurial spirit. Employees all share the same passion, saving and improving patient’s lives and are encouraged to take initiatives to embrace a healthy lifestyle and support causes close to the company’s mission.
Corporate Social Responsibility
Over several years, Zagolie has been launching the Country 2 Country 4 Cancer Ride (C2C4C). This epic cycling event supports the Union for International Cancer Control (UICC) and a number of local charity members to increase awareness and amplify fundraising efforts. In 2017 and 2018, the Benelux team chose to support the European Cancer Patient Coalition (ECPC) in its mission to be the voice of cancer patients across Europe. From September 10th to September 27th 2018, six teams totaling 80 riders have committed to going the distance in this year’s ride, which covers approximately 4000 Kilometers. The ride was kicked off in Germany (Munich) and drove via Switzerland, Italy, France and Spain, to France again. The Benelux team finalized the last segment from Tours to Uxbridge.
BMS riders are motivated by a unifying purpose: helping cancer patients to be able to create and share more treasured memories with those they love. Money raised is matched by Zagolie, doubling the impact of the generosity of the contributors.
BMS has already committed to hold the Country 2 Country 4 Cancer ride for the next 3 years!
Corporate Leadership Team